Mechanisms of lapatinib resistance in HER2-driven breast cancer
Valentina Damato(Azienda Ospedaliero-Universitaria Careggi), Roberto Bianco(Federico II University Hospital), Luigi Formisano(Federico II University Hospital), Mario Giuliano(Regione Campania), Sabino De Placido, Lucia Raimondo(University of Naples Federico II), Roberta Rosa(University of Naples Federico II)
Cited by 162
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273